CTDNEP1 has been identified as a tumor suppressor in highly aggressive Myc-driven medulloblastoma, and its deficiency is associated with poor patient prognosis (86), presenting a targetable therapeutic opportunity for drug discovery. Here, CTDNEP1 is linked to medulloblastoma.